Loading clinical trials...
Loading clinical trials...
Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL)
Conditions
Interventions
Isatuximab SAR650984
dexamethasone
+4 more
Locations
17
United States
Investigational Site Number 8400002
Atlanta, Georgia, United States
Investigational Site Number 8400003
Hackensack, New Jersey, United States
Investigational Site Number 8400001
Houston, Texas, United States
Investigational Site Number 2460001
Helsinki, Finland
Investigational Site Number 2500005
Nantes, France
Investigational Site Number 2500001
Paris, France
Start Date
March 8, 2017
Primary Completion Date
November 14, 2017
Completion Date
November 14, 2017
Last Updated
March 21, 2022
NCT05745714
NCT05658640
NCT07175415
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions